collection
https://read.qxmd.com/read/27437658/sudden-cardiac-death-after-non-st-segment-elevation-acute-coronary-syndrome
#21
JOURNAL ARTICLE
Paul L Hess, Daniel M Wojdyla, Sana M Al-Khatib, Yuliya Lokhnygina, Lars Wallentin, Paul W Armstrong, Matthew T Roe, E Magnus Ohman, Robert A Harrington, John H Alexander, Harvey D White, Frans Van de Werf, Jonathan P Piccini, Claes Held, Philip E Aylward, David J Moliterno, Kenneth W Mahaffey, Pierluigi Tricoci
IMPORTANCE: In the current therapeutic era, the risk for sudden cardiac death (SCD) after non-ST-segment elevation acute coronary syndrome (NSTE ACS) has not been characterized completely. OBJECTIVE: To determine the cumulative incidence of SCD during long-term follow-up after NSTE ACS, to develop a risk model and risk score for SCD after NSTE ACS, and to assess the association between recurrent events after the initial ACS presentation and the risk for SCD. DESIGN, SETTING, AND PARTICIPANTS: This pooled cohort analysis merged individual data from 48 286 participants in 4 trials: the Apixaban for Prevention of Acute Ischemic Events 2 (APPRAISE-2), Study of Platelet Inhibition and Patient Outcomes (PLATO), Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER), and Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trials...
April 1, 2016: JAMA Cardiology
https://read.qxmd.com/read/27323265/the-abc-stroke-risk-score-was-superior-to-the-cha2ds2-vasc-score-for-predicting-stroke-in-atrial-fibrillation
#22
COMMENT
Graeme J Hankey
No abstract text is available yet for this article.
June 21, 2016: Annals of Internal Medicine
https://read.qxmd.com/read/27207191/2016-esc-guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-failure-the-task-force-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-failure-of-the-european-society-of-cardiology-esc-developed-with-the-special-contribution-of-the
#23
JOURNAL ARTICLE
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker, Héctor Bueno, John G F Cleland, Andrew J S Coats, Volkmar Falk, José Ramón González-Juanatey, Veli-Pekka Harjola, Ewa A Jankowska, Mariell Jessup, Cecilia Linde, Petros Nihoyannopoulos, John T Parissis, Burkert Pieske, Jillian P Riley, Giuseppe M C Rosano, Luis M Ruilope, Frank Ruschitzka, Frans H Rutten, Peter van der Meer
No abstract text is available yet for this article.
August 2016: European Journal of Heart Failure
https://read.qxmd.com/read/17950797/effect-of-coenzyme-q-10-supplementation-on-simvastatin-induced-myalgia
#24
RANDOMIZED CONTROLLED TRIAL
Joanna M Young, Christopher M Florkowski, Sarah L Molyneux, Roberta G McEwan, Christopher M Frampton, Peter M George, Russell S Scott
Myalgia is the most frequently reported adverse side effect associated with statin therapy and often necessitates reduction in dose, or the cessation of therapy, compromising cardiovascular risk management. One postulated mechanism for statin-related myalgia is mitochondrial dysfunction through the depletion of coenzyme Q(10), a key component of the mitochondrial electron transport chain. This pilot study evaluated the effect of coenzyme Q(10) supplementation on statin tolerance and myalgia in patients with previous statin-related myalgia...
November 1, 2007: American Journal of Cardiology
https://read.qxmd.com/read/23458201/coenzyme-q-10-and-selenium-in-statin-associated-myopathy-treatment
#25
RANDOMIZED CONTROLLED TRIAL
Jan Fedacko, Daniel Pella, Petra Fedackova, Osmo Hänninen, Petri Tuomainen, Peter Jarcuska, Tomas Lopuchovsky, Lucia Jedlickova, Lucia Merkovska, Gian Paolo Littarru
The objective of this study was to evaluate the possible benefits of coenzyme Q10 and selenium supplementation administered to patients with statin-associated myopathy (SAM). Sixty eligible patients entered the pilot study. Laboratory examination (CoQ10, selenium, creatin kinase) and intensity of SAM (visual scale) were performed at baseline, after 1 month, and at the end of study at month 3. Plasma levels of CoQ10 increased from 0.81 ± 0.39 to 3.31 ± 1.72 μmol/L in the active group of patients treated by CoQ10, compared with the placebo (p = 0...
February 2013: Canadian Journal of Physiology and Pharmacology
https://read.qxmd.com/read/27166348/management-of-atrial-fibrillation-in-hypertrophic-cardiomyopathy
#26
REVIEW
Ciorsti MacIntyre, Neal K Lakdawala
No abstract text is available yet for this article.
May 10, 2016: Circulation
https://read.qxmd.com/read/26965621/rare-variant-in-scavenger-receptor-bi-raises-hdl-cholesterol-and-increases-risk-of-coronary-heart-disease
#27
JOURNAL ARTICLE
Paolo Zanoni, Sumeet A Khetarpal, Daniel B Larach, William F Hancock-Cerutti, John S Millar, Marina Cuchel, Stephanie DerOhannessian, Anatol Kontush, Praveen Surendran, Danish Saleheen, Stella Trompet, J Wouter Jukema, Anton De Craen, Panos Deloukas, Naveed Sattar, Ian Ford, Chris Packard, Abdullah al Shafi Majumder, Dewan S Alam, Emanuele Di Angelantonio, Goncalo Abecasis, Rajiv Chowdhury, Jeanette Erdmann, Børge G Nordestgaard, Sune F Nielsen, Anne Tybjærg-Hansen, Ruth Frikke Schmidt, Kari Kuulasmaa, Dajiang J Liu, Markus Perola, Stefan Blankenberg, Veikko Salomaa, Satu Männistö, Philippe Amouyel, Dominique Arveiler, Jean Ferrieres, Martina Müller-Nurasyid, Marco Ferrario, Frank Kee, Cristen J Willer, Nilesh Samani, Heribert Schunkert, Adam S Butterworth, Joanna M M Howson, Gina M Peloso, Nathan O Stitziel, John Danesh, Sekar Kathiresan, Daniel J Rader
Scavenger receptor BI (SR-BI) is the major receptor for high-density lipoprotein (HDL) cholesterol (HDL-C). In humans, high amounts of HDL-C in plasma are associated with a lower risk of coronary heart disease (CHD). Mice that have depleted Scarb1 (SR-BI knockout mice) have markedly elevated HDL-C levels but, paradoxically, increased atherosclerosis. The impact of SR-BI on HDL metabolism and CHD risk in humans remains unclear. Through targeted sequencing of coding regions of lipid-modifying genes in 328 individuals with extremely high plasma HDL-C levels, we identified a homozygote for a loss-of-function variant, in which leucine replaces proline 376 (P376L), in SCARB1, the gene encoding SR-BI...
March 11, 2016: Science
https://read.qxmd.com/read/27006716/stent-thrombosis-after-rescue-percutaneous-coronary-intervention-in-acute-st-segment-elevation-myocardial-infarction
#28
JOURNAL ARTICLE
Khalid Bin Thani, Fajer Al-Moosa, Eman Murad, Aisha Al-Moosa, Mohamed E Alalawi, Hind Al-Sindi
MAIN PROBLEM: To determine the incidence of coronary stent thrombosis (ST) in patients with acute ST segment elevation myocardial infarction (STEMI) after rescue percutaneous coronary intervention (PCI). METHODS: An observational study looking at the incidence of ST in a middle-eastern population. A total of 510 consecutive patients presented with ST-segment elevation myocardial infarction (STEMI) were enrolled and underwent thrombolytic therapy with a total follow-up period of 2 years...
2015: Open Cardiovascular Medicine Journal
https://read.qxmd.com/read/27195814/intensive-vs-standard-blood-pressure-control-and-cardiovascular-disease-outcomes-in-adults-aged-%C3%A2-75-years-a-randomized-clinical-trial
#29
RANDOMIZED CONTROLLED TRIAL
Jeff D Williamson, Mark A Supiano, William B Applegate, Dan R Berlowitz, Ruth C Campbell, Glenn M Chertow, Larry J Fine, William E Haley, Amret T Hawfield, Joachim H Ix, Dalane W Kitzman, John B Kostis, Marie A Krousel-Wood, Lenore J Launer, Suzanne Oparil, Carlos J Rodriguez, Christianne L Roumie, Ronald I Shorr, Kaycee M Sink, Virginia G Wadley, Paul K Whelton, Jeffrey Whittle, Nancy F Woolard, Jackson T Wright, Nicholas M Pajewski
IMPORTANCE: The appropriate treatment target for systolic blood pressure (SBP) in older patients with hypertension remains uncertain. OBJECTIVE: To evaluate the effects of intensive (<120 mm Hg) compared with standard (<140 mm Hg) SBP targets in persons aged 75 years or older with hypertension but without diabetes. DESIGN, SETTING, AND PARTICIPANTS: A multicenter, randomized clinical trial of patients aged 75 years or older who participated in the Systolic Blood Pressure Intervention Trial (SPRINT)...
June 28, 2016: JAMA
https://read.qxmd.com/read/27216111/2016-acc-aha-hfsa-focused-update-on-new-pharmacological-therapy-for-heart-failure-an-update-of-the-2013-accf-aha-guideline-for-the-management-of-heart-failure-a-report-of-the-american-college-of-cardiology-american-heart-association-task%C3%A2-force%C3%A2-on%C3%A2-clinical
#30
JOURNAL ARTICLE
Clyde W Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E Casey, Monica M Colvin, Mark H Drazner, Gerasimos Filippatos, Gregg C Fonarow, Michael M Givertz, Steven M Hollenberg, JoAnn Lindenfeld, Frederick A Masoudi, Patrick E McBride, Pamela N Peterson, Lynne Warner Stevenson, Cheryl Westlake
No abstract text is available yet for this article.
September 27, 2016: Journal of the American College of Cardiology
https://read.qxmd.com/read/27179724/risk-and-timing-of-recurrent-ischemic-events-among-patients-with-stable-ischemic-heart-disease-non-st-segment-elevation-acute-coronary-syndrome-and-st-segment-elevation-myocardial-infarction
#31
RANDOMIZED CONTROLLED TRIAL
Thomas Pilgrim, Pascal Vranckx, Marco Valgimigli, Giulio G Stefanini, Raffaele Piccolo, Julie Rat, Martina Rothenbühler, Stefan Stortecky, Lorenz Räber, Stefan Blöchlinger, Lukas Hunziker, Sigmund Silber, Peter Jüni, Patrick W Serruys, Stephan Windecker
BACKGROUND: We aimed to compare differences in risk and timing of recurrent ischemic events among patients with stable ischemic heart disease (SIHD), non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). METHODS: We performed an individual data pooled analysis of 5 randomized controlled all-comer trials including a total of 8,859 patients and investigated the risk and timing of recurrent ischemic events among patients with SIHD (n = 3,543), NSTE-ACS (n = 3,364), and STEMI (n = 1,952) throughout 2 years of follow-up...
May 2016: American Heart Journal
https://read.qxmd.com/read/27219741/echocardiographic-features-that-may-predict-acute-left-ventricular-failure-after-mitral-valve-replacement-in-patients-with-severe-mitral-stenosis
#32
REVIEW
Michael K Essandoh
No abstract text is available yet for this article.
October 2016: Anesthesiology
https://read.qxmd.com/read/27164184/arrhythmia-risk-stratification-of-patients-after-myocardial-infarction-using-personalized-heart-models
#33
JOURNAL ARTICLE
Hermenegild J Arevalo, Fijoy Vadakkumpadan, Eliseo Guallar, Alexander Jebb, Peter Malamas, Katherine C Wu, Natalia A Trayanova
Sudden cardiac death (SCD) from arrhythmias is a leading cause of mortality. For patients at high SCD risk, prophylactic insertion of implantable cardioverter defibrillators (ICDs) reduces mortality. Current approaches to identify patients at risk for arrhythmia are, however, of low sensitivity and specificity, which results in a low rate of appropriate ICD therapy. Here, we develop a personalized approach to assess SCD risk in post-infarction patients based on cardiac imaging and computational modelling. We construct personalized three-dimensional computer models of post-infarction hearts from patients' clinical magnetic resonance imaging data and assess the propensity of each model to develop arrhythmia...
May 10, 2016: Nature Communications
https://read.qxmd.com/read/27124268/managing-multivessel-coronary-artery-disease-in-patients-with-st-elevation-myocardial-infarction-a-comprehensive-review
#34
REVIEW
Andrés M Pineda, Nikita Carvalho, Saqib A Gowani, Kavit A Desouza, Orlando Santana, Christos G Mihos, Gregg W Stone, Nirat Beohar
Multivessel coronary artery disease (CAD) is found in up to 60% of the patients presenting with an ST-elevation myocardial infarction (STEMI) and worsens the prognosis proportional to the extent of CAD severity. However, the 2013 American College of Cardiology/American Heart Association STEMI guidelines, based on mostly observational data, had recommended against a routine noninfarct-related artery percutaneous coronary intervention (PCI). After these guidelines were published, a handful of randomized trials became available, and they suggested that PCI of significant lesions in a noninfarct-related artery at the time of primary PCI might result in improved patient outcomes...
July 2017: Cardiology in Review
https://read.qxmd.com/read/27036919/duration-of-dual-antiplatelet-therapy-a-systematic-review-for-the-2016-acc-aha-guideline-focused-update-on-duration-of-dual-antiplatelet-therapy-in-patients-with-coronary%C3%A2-artery-disease-a-report-of-the-american-college-of-cardiology-american-heart-association
#35
REVIEW
John A Bittl, Usman Baber, Steven M Bradley, Duminda N Wijeysundera
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after implantation of newer-generation drug-eluting stents (DES) remains uncertain. Similarly, questions remain about the role of DAPT in long-term therapy of stable post-myocardial infarction (MI) patients. AIM: Our objective was to compare the incidence of death, major hemorrhage, MI, stent thrombosis, and major adverse cardiac events in patients randomized to prolonged or short-course DAPT after implantation of newer-generation DES and in secondary prevention after MI...
September 6, 2016: Journal of the American College of Cardiology
https://read.qxmd.com/read/27026019/duration-of-dual-antiplatelet-therapy-a-systematic-review-for-the-2016-acc-aha-guideline-focused-update-on-duration-of-dual-antiplatelet-therapy-in-patients-with-coronary-artery-disease-a-report-of-the-american-college-of-cardiology-american-heart-association
#36
REVIEW
John A Bittl, Usman Baber, Steven M Bradley, Duminda N Wijeysundera
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after implantation of newer-generation drug-eluting stents (DES) remains uncertain. Similarly, questions remain about the role of DAPT in long-term therapy of stable post-myocardial infarction (MI) patients. AIM: Our objective was to compare the incidence of death, major hemorrhage, MI, stent thrombosis, and major adverse cardiac events in patients randomized to prolonged or short-course DAPT after implantation of newer-generation DES and in secondary prevention after MI...
September 6, 2016: Circulation
https://read.qxmd.com/read/27037852/two-drugs-are-better-than-one-%C3%A2-for-a-while-duration-of-dual-antiplatelet-therapy-following-stroke-or-transient-ischaemic-attack
#37
EDITORIAL
J P Klaas
No abstract text is available yet for this article.
June 2016: European Journal of Neurology
https://read.qxmd.com/read/27026020/2016-acc-aha-guideline-focused-update-on-duration-of-dual-antiplatelet-therapy-in-patients-with-coronary-artery-disease-a-report-of-the-american-college-of-cardiology-american-heart-association-task-force-on-clinical-practice-guidelines-an-update-of-the-2011
#38
REVIEW
https://read.qxmd.com/read/26995592/contemporary-management-of-acute-right-ventricular-failure-a-statement-from-the-heart-failure-association-and-the-working-group-on-pulmonary-circulation-and-right-ventricular-function-of-the-european-society-of-cardiology
#39
REVIEW
Veli-Pekka Harjola, Alexandre Mebazaa, Jelena Čelutkienė, Dominique Bettex, Hector Bueno, Ovidiu Chioncel, Maria G Crespo-Leiro, Volkmar Falk, Gerasimos Filippatos, Simon Gibbs, Adelino Leite-Moreira, Johan Lassus, Josep Masip, Christian Mueller, Wilfried Mullens, Robert Naeije, Anton Vonk Nordegraaf, John Parissis, Jillian P Riley, Arsen Ristic, Giuseppe Rosano, Alain Rudiger, Frank Ruschitzka, Petar Seferovic, Benjamin Sztrymf, Antoine Vieillard-Baron, Mehmet Birhan Yilmaz, Stavros Konstantinides
Acute right ventricular (RV) failure is a complex clinical syndrome that results from many causes. Research efforts have disproportionately focused on the failing left ventricle, but recently the need has been recognized to achieve a more comprehensive understanding of RV anatomy, physiology, and pathophysiology, and of management approaches. Right ventricular mechanics and function are altered in the setting of either pressure overload or volume overload. Failure may also result from a primary reduction of myocardial contractility owing to ischaemia, cardiomyopathy, or arrhythmia...
March 2016: European Journal of Heart Failure
https://read.qxmd.com/read/26918015/a-modified-heart-risk-score-in-chest-pain-patients-with-suspected-non-st-segment-elevation-acute-coronary-syndrome
#40
JOURNAL ARTICLE
Chun-Peng Ma, Xiao Wang, Qing-Sheng Wang, Xiao-Li Liu, Xiao-Nan He, Shao-Ping Nie
OBJECTIVE: To validate a modified HEART [History, Electrocardiograph (ECG), Age, Risk factors and Troponin] risk score in chest pain patients with suspected non-ST-segment elevation acute coronary syndrome (NSTE-ACS) in the emergency department (ED). METHODS: This retrospective cohort study used a prospectively acquired database and chest pain patients admitted to the emergency department with suspected NSTE-ACS were enrolled. Data recorded on arrival at the ED were used...
January 2016: Journal of Geriatric Cardiology: JGC
label_collection
label_collection
3418
2
3
2016-03-10 23:25:33
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.